Known safety concerns, contraindications, and risk factors.
Active malignancy
Proangiogenic peptides may accelerate tumor growth and metastasis in individuals with active or suspected cancer.
Pregnancy or lactation
No safety data exists for use during pregnancy or lactation. Proliferative and angiogenic effects pose unknown risks to fetal development.
Competitive athletes subject to WADA testing
BPC-157 and TB-500 are on the WADA prohibited substances list. Use will result in anti-doping violations.
Concurrent anticoagulant therapy
Angiogenic peptides may interact with anticoagulant medications, potentially altering bleeding risk or vascular integrity.
Organ dysfunction
Impaired hepatic or renal function may alter peptide metabolism and clearance, increasing risk of adverse effects.